The major players in the obesity GLP-1 market include Novo Nordisk A/S, Eli Lilly and Company, Amgen, Viking Therapeutic, AstraZeneca, Roche (Carmot Therapeutics), Boehringer Ingelheim, Pfizer Inc., Altimmune, Inc., and Structure Therapeutics
Tabrizi SJ, Flower MD, Ross CA, Wild EJ
The real difference is that Wegovy extends to a higher ceiling of 25 mg, and higher doses are generally associated with greater weight loss, which is one reason it tends to be the better fit if weight loss is your primary goal
Why it matters: Clinical trials are controlled and selective
The key is choosing complex, low-glycemic carbohydrates like oats, brown rice, quinoa, sweet potatoes, and whole grain bread rather than refined or sugary options
Click below to schedule a Consultation with one of our Mold Professionals